Europe Epigenetics Market 2023 Top Key Players are DIAGENODE, ILLUMINA, MERCK & CO., QIAGEN, EPITHERAPEUTICS, THERMO FISHER SCIENTIFIC, ZYMO RESEARCH CORPORATION

Europe Epigenetics Market Highlights
The Europe epigenetics market is estimated to register a high CAGR during the forecast period. Epigenetics is defined as the study of changes in gene expression, which is caused by certain base pairs in DNA, or RNA, being turned off or on again, through the chemical reactions.

Get your sample report now @ https://marketprognosis.com/sample-request/16903
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Rising Cost of Instruments
The epigenetic instruments cost is rising gradually, and this increase is becoming one of the major restrains for the growth of the market. The instruments, such as mass spectrometers, sonicators, and the next generation sequences, are already costly, and the rising cost of these instruments are going to increase the cost for the genetic test, which simultaneously decreases the adoption rate of epigenetic instruments. Additionally, lack of skilled researchers is restraining the market growth of epigenetics.t

Key Developments in the Market
• December 2017 - Roche and Ignyta made definitive merger agreement (Roche to fully acquire Ignyta)
• December 2017 - Zymo Research collaborated with Bertin

Major Players:
DIAGENODE INC, ILLUMINA INC, MERCK & CO., QIAGEN, EPITHERAPEUTICS, THERMO FISHER SCIENTIFIC, ZYMO RESEARCH CORPORATION, AND ROCHE, among others.

Get Discount on this report @ https://marketprognosis.com/discount-request/16903
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

The Germany has the Highest Market Share
In Europe, the Germany is dominating the epigenetics market due to the factors, such as increasing prevalence rate of cancer, increasing funding for the R&D, and the increasing collaborations between several large pharmaceutical companies for development of enhanced therapeutics.

Increasing Incidence and Prevalence of Cancer
According to WHO, more than 3.7 million of new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in Europe.
Europe comprises of only 1/8th of the total world population but it has around one quarter of the global total of cancer cases with 3.7 million new patients per year. This depicts the large patient pool of cancer patients, which will propel the growth of the epigenetics market. As this epigenetics is used in the study of changes in gene expression, which are useful in the cancer diagnosis. So, with the increasing cancer prevalence the market is expected to grow. The other factors, like increasing funding for R&D in healthcare and the rising epigenetic applications in non-oncology diseases, are driving the epigenetics market.

For More Information, Please Visit @ https://marketprognosis.com/enquiry/16903
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.